Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with myelodysplastic syndromes (MDSs). We have analyzed the outcome of 81 patients who underwent an allogeneic transplant from an HLA-identical sibling donor. The overall survival (OS) was 31% and disease-free survival was 30% at 5.8 years. Transplant-related complications were the cause of death in 44% and disease progression in 16% of patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 32 cases (39%). Extensive chronic GVHD (cGVHD) was observed in 27% of patients. When the log-rank test was performed, we observed that patients transplanted more than 6 months after diagnosis, and those transplanted with bone marrow (BM) displayed a shorter survival (P ¼ 0.009 and 0.005, respectively). Patients who developed cGVHD showed a trend towards better OS (P ¼ 0.07). Patients receiving BM had a higher incidence of aGVHD (65 vs 50%) and less cGVHD (52 vs 30%), although the differences did not reach statistical significance. Moreover, patients who received PB-HSC displayed a faster engraftment (P ¼ 0.000) and showed a significantly lower early transplant-related mortality (14 vs 42%; P ¼ 0.006) and longer OS (P ¼ 0.005). In summary, our results show that hematopoietic transplantation should be performed as soon as possible in MDS patients and that PB is preferable to BM as a source of HSC. 
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with myelodysplastic syndromes (MDSs). We have analyzed the outcome of 81 patients who underwent an allogeneic transplant from an HLA-identical sibling donor. The overall survival (OS) was 31% and disease-free survival was 30% at 5.8 years. Transplant-related complications were the cause of death in 44% and disease progression in 16% of patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 32 cases (39%). Extensive chronic GVHD (cGVHD) was observed in 27% of patients. When the log-rank test was performed, we observed that patients transplanted more than 6 months after diagnosis, and those transplanted with bone marrow (BM) displayed a shorter survival (P ¼ 0.009 and 0.005, respectively). Patients who developed cGVHD showed a trend towards better OS (P ¼ 0.07). Patients receiving BM had a higher incidence of aGVHD (65 vs 50%) and less cGVHD (52 vs 30%), although the differences did not reach statistical significance. Moreover, patients who received PB-HSC displayed a faster engraftment (P ¼ 0.000) and showed a significantly lower early transplant-related mortality (14 vs 42%; P ¼ 0.006) and longer OS (P ¼ 0.005). In summary, our results show that hematopoietic transplantation should be performed as soon as possible in MDS patients and that PB is preferable to BM as a source of HSC. The clinical course is highly variable with survival ranging from weeks to several years. 3, 4 Treatment options for MDS are limited. Allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), using either BM or PB, is the only curative therapy for these patients. 5, 6 Several risk factors predicting clinical evolution after allogeneic transplantation have been described such as disease stage, proportion of blast cells in BM, age, cytogenetic aberrations, disease duration and IPSS score. [7] [8] [9] [10] [11] [12] [13] The present report analyzes the outcome of 81 patients who have been reported to the Spanish registry for hematopoietic cell transplantation (Grupo Espan˜ol de Trasplante Hematopoye´tico, GETH), who underwent an allogeneic transplant from an HLA-identical sibling donor. In previous reports, it has been shown that in the allogeneic transplantation setting for MDS patients, there is a high transplant-related mortality (TRM). [7] [8] [9] [10] [11] [12] Other authors have observed that faster engraftment is achieved in hematological malignancies when PB is used as the cell source instead of BM. 14, 15 Based on these findings, special attention was paid to differences between BM and PB as a source of HSCT in the present series.
Patients and methods
Between 1985 and 2001, 81 patients with 'de novo' MDS, who underwent an allogeneic HSCT, were included in the registry. Their clinical characteristics are listed in Table 1 . The median age was 39 years (range 8-52). Patients were classified according to FAB criteria. Three cases had been treated and were in complete remission at the time of transplantation and eight cases had progressed to secondary acute myeloblastic leukemia, four in the BM group and four in the PB group. In all, 42 patients received busulfan and cyclophosphamide as the conditioning regimen, 32 received cyclophosphamide and TBI and the remaining seven patients received other conditioning regimens. In the majority of cases, (64%) cyclosporin A (CSA) and methotrexate were used for graft-versus-host disease (GVHD) prophylaxis, while 13% received CSA and prednisone, and in the remaining patients, other prophylactic schemes were used. T-cell depletion was only performed in one patient.
Statistical analysis
Survival curves were calculated using the Kaplan-Meier method with the date of transplant as the starting point. For evaluation of event-free survival (EFS), patients were censored at the time of relapse/death or at the time of last follow-up if still alive and without relapse. For overall survival (OS), the event was death or the time of last follow-up. The log-rank test was used for comparison of Kaplan-Meier curves.
A Cox regression analysis was performed and the following variables have been included in the analysis: age, FAB MDS subtype, disease duration until transplantation, source of hematopoietic progenitor cells (HPC), year of transplantation and the presence or otherwise of GVHD. In addition, data comparing BM and PB as HPC source were also analyzed.
Results
The median time elapsed from diagnosis to transplant was 8 months (range 0.5-170) and median follow-up was 8.5 months (range 0.5-175). Two patients did not achieve engraftment. In total, 53 patients had died by the time of the analysis.
OS was 31% at 5.8 years with a median survival time of 10.5 months (Figure 1a ). EFS was 30% (Figure 1b) . Transplant-related complications were the cause of death in 36 cases (44%) and disease progression in 13 cases (16%) ( Table 2 ). The most common cause of death was infectious complications (47%). In nine patients (17%), death was directly attributed to GVHD complications.
Clinically significant acute GVHD (aGVHD) (grades II-IV) occurred in 32 cases (39%). Limited chronic GVHD (cGVHD) was observed in 15% of patients and extensive in 27%. 
Prognostic factors
In the Cox analysis, none of the variables analyzed showed a significant impact on survival. In order to analyze the most relevant parameters influencing disease evolution, the log-rank test was performed. Patients transplanted more than 6 months after diagnosis showed shorter OS that was statistically significant when compared with patients transplanted prior to 6 months after diagnosis (OS 52.28 vs 17.6%; P ¼ 0.009) (Figure 2a ). When we analyzed whether or not the time elapsed from diagnosis to transplantation was similar in RAEB þ RAEB-t patients vs the other MDS cases, we found that there was no significant difference (median time 8 vs 12 months, respectively; P ¼ NS). Also, patients transplanted with BM as the cell source showed statistically significant shorter survival (P ¼ 0.04) ( Table 3) . Patients who developed chronic GVHD showed a trend towards better EFS (P ¼ 0.07) (Table 3, Figure 2b ). In order to ascertain whether more advanced disease resulted in a survival that differed from other subtypes, RAEB and RAEB-t and other MDS patients were analyzed separately. Results are shown in Figure 3a and b. No differences were found, for either OS or EFS.
PB or BM as an HPC source
In order to determine why patients receiving PB as the HPC source showed a better survival, we further characterized and compared the two groups of patients. We observed that patients receiving BM showed a trend to develop aGVHD more frequently (P ¼ 0.08) and cGVHD less frequently than PB-transplanted patients, although the differences did not reach statistical significance (Table 4) . Moreover, patients who received PB-HSC engrafted significantly faster than those who received BM cells (Po0.05) and also showed a significantly lower early transplant-related mortality (TRM) (death in the first 100 days after transplantation) (P ¼ 0.006). In total, 26 patients died in the first 100 days after transplantation: eight (30.8%) from bleeding, 11 (42%) from infection not specified, two (7.6%) from progression and three (11.5%) from GVHD ( Table 4) . The probability of early TRM was lower when PB was used as the source of HPC instead of BM (Figure 4 ). When late mortality was considered, we observed that there was no difference between either of the groups of patients with a median follow-up of 2 years (P ¼ 0.4). In all, 17 patients relapsed, 10 patients transplanted with PBSC and seven with BM. There was no significant difference in the actuarial probability of relapse at 5 years: 35% for BM (95% CI 14-54) compared with 36% for PBSC (95% CI 28-55) ( Figure 5) .
In order to ascertain whether the cell source had a positive impact on the different groups of MDS, we separately analyzed the OS and EFS in high-risk patients (RAEB and RAEB-t) and low-risk patients (RA and RARS). We confirmed that OS and EFS is longer when PB is used as the cell source in the high-risk group (Figure  6a and b) . Also, in the low-risk group, patients showed a longer OS and EFS, although differences did not reach statistical significance (48 vs 31 and 46 vs 25%, respectively; P ¼ NS). 
Discussion
Although limited by the patient's age, allogeneic HSCT is the only curative treatment for MDS patients. 5, 6 Here, we report the results of allogeneic HSCT in a series of patients with 'de novo' MDS included in the Spanish registry (GETH). The OS and EFS in the present series were comparable to those reported in similar series in which OS ranged between 32 and 41% at 3-7 years. [7] [8] [9] [10] [11] [12] [13] Several disease characteristics such as patient's age, disease stage, percentage of BM blast cells, time elapsed from diagnosis and cytogenetic data have been shown to have an impact on survival from MDS after allogeneic HSCT. [7] [8] [9] [10] [11] [12] In the present series, karyotype could not be analyzed because it was not available in a significant number of patients. The two variables that showed the most significant impact on OS were disease duration until the HSCT procedure and the source of HSC for transplantation (BM vs PB). It has been stressed previously that, when indicated, transplantation should be carried out in MDS patients as soon as possible before the development of iron overload and opportunistic infections, and also before transformation to a more advanced stage of MDS. 10 Our data concur with this suggestion; patients transplanted during the first 6 months after diagnosis showed better survival (median 52 vs 18 months).
The second variable that showed a prognostic impact was the source of HPC: patients transplanted with PB progenitor cells had a longer OS. It has previously been shown that engraftment after transplantation is faster when PB progenitors are used instead of BM-HPC [14] [15] [16] [17] [18] , but the impact on OS may be counterbalanced by a higher rate of GVHD. 17, 18 The present analysis shows that, at least in 'de novo' MDS patients, the use of PB leads to a longer survival when compared with BM-transplanted patients. These results support those reported by Guardiola et al, 19 who observed better survival for MDSA patients, who received PB HPC when compared with those receiving cells from BM, except for RA and patients with high-risk cytogenetics. One of the most important causes of the poor survival observed in patients with MDS receiving hematopoietic transplantation is the high rate of early TRM. [7] [8] [9] [10] [11] [12] In addition, it has recently been reported that in AML and MDS patients, a graft-versus-leukemia effect may exist since the presence of cGVHD was associated with a significant better DFS. 20 The rapid engraftment achieved upon using PB-HSC with the subsequent reduction in infectious complications, together with the trend towards lower incidence of aGVHD in patients receiving PB-HSC may lead to a decrease in early TRM of MDS patients. Moreover, the higher proportion of cGVHD with similar late TRM rates could prevent disease relapse. However, our results on GVHD incidence must be interpreted with caution because different prophylactic regimens have been applied.
When the different risk groups were evaluated, we observed that, although survival was longer when PB was used in both high-and low-risk patients, the high-risk group appeared to benefit more.
In summary, our data shows that young patients diagnosed with MDS, when indicated and with a suitable donor, must be transplanted as soon as possible and preferably with PB hematopoietic progenitor cells. 
